Title

METHOTREXATE : SURGICAL CASE SERIES.

Summary

Introduction: Methotrexate (MTX) is a drug that acts by inhibiting dihydrofolate reductase and blocking the synthesis of DNA and RNA. MTX has been introduced with good results for the prevention of vitreoretinal proliferation (PVR) in retinal detachment. PVR occurs in 5-10% of cases of retinal detachment (RD), but corresponds to 75% of the causes of retinal redetachment. Aim: To evaluate the use of MTX infusion in the BSS associated with a single injection of MTX at the end of surgery for PVR prophylaxis. Methods: A retrospective review was performed on a cohort of thirteen consecutive eyes with retinal detachment undergoing pars plana vitrectomy (PPV) by RD with the use of Methotrexate infusion in the BSS associated with a single intravitreal injection of MTX at a dose of 200 to 400 µ at the end of the surgical procedure. Results: In the whole group, two patients (15,39%) evolved with formation of PVR and only one of them with associated RD, being necessary to undergo a new procedure. We did not observe any surgical complications during the operation. Conclusions: The use of methotrexate infusion associated with a single intravitreal injection at the end of the procedure showed absence of PVR formation in 84.61% of cases.

Area

SURGICAL CASE

Authors

Bianca Luiza Valduga Guareschi, Ligia Cury, Danilo Aedo Gardim Camilo, Juliana Kirsten Carpes, Camila Winckler, Luiz Gustavo Sanches, Diogo Rodrigo da Silva, João Guilherme Oliveira de Moraes